- Lid geworden
- 30 apr 2008
- Berichten
- 2.573
- Waardering
- 152
Alflutop
Drug Classification: Chondroprotector
Active Life: approximately 24-36 hours
Alflutop is the trademarked name of a product produced by the pharmaceutical company Biotehnos. The Alflutop produced by this company contains sea fish bioactive concentrate, which itself contains low molecular mass peptides, mucopolysaccharides, and amino acids. Also included are trace elements including zinc, copper, sodium, calcium, iron, and magnesium. Most often the compound is packaged in one milliliter amps which each contain ten milligrams of sea fish bioactive concentrate, as well as phenol which possesses anesthetic properties as well as acting as a preservative.
The medical use of Alflutop is primarily for the treatment of degenerative joint disorders such as tendonitis, ankylopoietic spondilitis, bursitis, spinal disc injuries and arthritis-related disorders (1). Obviously these are the same uses that bodybuilders and strength athletes will want to utilize Alflutop for as well.
Alflutop works in numerous ways to help stop tissue damage from happening in joints, while also repairing tissues that have already been damaged. This occurs via cartilage regeneration and a reduction in free radical damage within joint tissues. As well, the contents of Alflutop help to inhibit overproduction of hyaluronidase, an enzyme that catalyzes the breakdown of hyaluronic acid in the tissues of the body. Excessive production of this enzyme can lead to serious damage within joints. Alflutop will also help to restore and maintain homeostasis within chondrocytes, the structures responsible for the production and maintenance of the extracellular matrix of cartilage.
Along with the injectable version of Alflutop, Biotehnos also produces a topical ointment as well as a suppository form of the compound. However both of these forms of the drug will of course be less efficient as a delivery method of the compound and less effective. The injectable version of Alflutop is also the more commonly found form of the compound. For these reasons, the majority of users will want to administer the drug via injections.
Use/Dosing
Due to the active life of the compound, frequent dosing is required. For the most part, most users find that injecting one amp, 10mgs sea fish bioactive concentrate or one milliliter in volume, every day or every other day for a period of approximately twenty-one days will bring substantial relief in the majority of their symptoms as they relate to joint discomfort and/or damage. However this protocol has basically been devised by way of anecdotal information passed on from one user to another. In clinical trials the length of administering the drug has ranged from less then seven days to as long as several months. It was found that various lengths of time were needed to treated individuals and these were based on several factors including the amount of damage/trauma that was inflicted upon the joint(s), how well the individual reacted to the drug, and how much physical activity and recuperation methods the individuals used in conjunction with the drug treatment, among others. For this reason, no set standard needs to be adhered to when using Alflutop and the length of use should be determined by the results achieved with the compound.
The injectable version of Alflutop is administered via intramuscular injections. It seemingly does not matter which muscles that the compound is injected into as it will affect all of the joints of the user equally. There is no additional benefit to administering the drug into the area of the injury or trauma. This, along with the frequency of the injections, would allow the user to spread the injections throughout several muscle groups so as not to cause undue irritation to the muscles that the compound is being administered to.
In terms of use for females, it appears that the same dosages can be translated to women as they are for men. No real changes to the volume or frequency of the dosing of the drug need to be made, with no increase of severity or frequency of potential side effects being seen in women.
Like the duration of the administration of the drug, the frequency with which a user chooses to cycle the compound seemingly will not be hindered by side effects either. If one chooses to run Alflutop several times within a short period of time, this appears to be beneficial. In fact in the case of rheumatoid arthritis, this is the protocol for treatment using the drug in many cases (2). However anecdotally users have reported only needing to use the compound once or twice for years at a time and have never had a reoccurrence of their symptoms. Of course, a number of factors could also contribute to this, most notably being that most would not subject themselves to the activity that had caused the initial damage or trauma in the first place.
Risks/Side Effects
From the available research that has thus far been conducted it seems that Alflutop is well tolerated by nearly all subjects that have received it as treatment. It is also important to note that the vast majority of this research has been completed using elderly patients due to the research primarily concerning itself with use of the drug in those individuals who suffer from rheumatoid arthritis, among other conditions. This is important since many of these older patients may suffer from other age related diseases and/or conditions. From the research that has been conducted it appears that Alflutop has had not negative effects on those patients suffering from heart conditions, gastrointestinal distress/diseases or diseases of the thyroid (2, 3). Obviously these findings should also presumably hold true for younger, healthier individuals.
The only real negative side effects associated with the administration of Alflutop are some reports of irritation related to the frequent injections. Some post-injection pain was noted by some patients while others tolerated the frequent injections well. However no major complications related to the injections were reported in the available research and literature related to Alflutop.
Alflutop Profile ~ By Aboot
References:
1. Noskov SM, Fetelego OI, Krasivina IG, Dolgova LN. [Alflutop in local therapy of shoulder periarthritis] Ter Arkh. 2005;77(8):57-60.
2. Svetlova MS, Ignat'ev VK. [Use of alflutop in the treatment of patients with osteoarthrosis] Klin Med (Mosk). 2004;82(6):52-5.
3. Taran AI, Puzanova OG, Lapenko OIe, Sol's'kyi VI, Samoilova SM. [Experience gained with the use of local administration of medicinal remedies in rheumatic diseases] Lik Sprava. 2001 Sep-Dec;(5-6):182-5.
2. Svetlova MS, Ignat'ev VK. [Use of alflutop in the treatment of patients with osteoarthrosis] Klin Med (Mosk). 2004;82(6):52-5.
3. Taran AI, Puzanova OG, Lapenko OIe, Sol's'kyi VI, Samoilova SM. [Experience gained with the use of local administration of medicinal remedies in rheumatic diseases] Lik Sprava. 2001 Sep-Dec;(5-6):182-5.
Adequan
De menselijke variant van Adequan is Arteparon, deze wordt echter niet meer verkocht.
De menselijke variant van Adequan is Arteparon, deze wordt echter niet meer verkocht.
First, Adequan has important antiinflammatory effects, so it is able to provide relief from the symptoms of joint damage: heat, swelling, pain and lameness. And Adequancan be found in synovial fluid at full therapeutic levels within only two hours of an intramuscular injection. Also, Adequan is a product with potent ability to block the action of the destructive enzymes that threaten to perpetuate the joint inflammation, attack the cartilage and break down synovial fluid.
Second, Adequan also stimulates the synovial membrane to manufacture new, viscous synovial fluid to replace the thin fluid that was produced when the joint became injured. By improving this fluid, Adequan helps the joint regain its ability to lubricate and guard itself against further inflammation, and helps reestablish nutrition to the cartilage.
And, Adequan attaches itself to damaged cartilage where it has a positive effect on cartilage metabolism. This should favor the cartilage repair process.
Adequan is the only joint treatment proven to reduce the inflammation and pain of degenerative joint disease, but also to help stop the degenerative process while stimulating the production of new joint fluid and new cartilage components. You are no longer just treating symptoms: you're doing something to help stop the degenerative process.
DOSAGE AND ADMINISTRATION: The recommended dose of Adequan IM in horses is 500mg every 4 days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan IM with other drugs or solvents. Dit gaat dus over paarden, voor menselijk gebruik is dit 125mg IM elke 3 dagen.
FAST ACCESS TO THE JOINTS: Beneficial levels of Adequan are already at work in all major joints within two hours after intramuscular injection, with even greater uptake (up to 73% higher) in joint tissues that are inflamed or diseased. LONG-TERM EFFECTS: Adequan relieves the pain and disability of joint damage, and the relief has been shown to last up to 6 months or longer.
BREAKS THE DESTRUCTIVE CYCLE: Adequan binds to damaged cartilage and boosts cartilage metabolism, facilitating repair processes. At the same time, it blocks the action of destructive enzymes that promote joint inflammation, break down the synovial fluid, and attack the cartilage. RENEWS THE JOINT FLUID: Adequan stimulates the synovial membrane to manufacture new synovial fluid to replace the thin, degraded fluid of joint disease. By doing so, Adequan helps lubricate, nourish, and clean the cartilage.
Indications
Adequan Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
Pharmacology
The active ingredient in Adequan Canine is polysulfated glycosaminoglycan (PSGAG). Polysulfated glycosaminoglycan is a semi-synthetic glycosaminoglycan prepared by extracting glycosaminoglycans (GAGs) from bovine tracheal cartilage. GAGs are polysaccharides composed of repeating disaccharide units. The GAG present in PSGAG is principally chondroitin sulfate containing 3 to 4 sulfate esters per disaccharide unit. The molecular weight for PSGAG used in the manufacture of Adequan is 3,000 to 15,000 Daltons.
The specific mechanism of action of Adequan in canine joints is not known. PSGAG is characterized as a "disease modifying osteoarthritis drug". Experiments conducted in vitro have shown PSGAG to inhibit certain catabolic enzymes which have increased activity in inflamed joints, and to enhance the activity of some anabolic enzymes. For example, PSGAG has been shown to significantly inhibit serine proteinases. Serine proteinases have been demonstrated to play a role in the Interleukin-1 mediated degradation of cartilage proteoglycans and collagen. PSGAG is reported to be an inhibitor of Prostaglandin E2 (PGE2) synthesis. PGE2 has been shown to increase the loss of proteoglycan from cartilage. PSGAG has been reported to inhibit some catabolic enzymes such as elastase, stromelysin, metalloproteases, cathepsin B1, and hyaluronidases, which degrade collagen, proteoglycans, and Hyaluronic acid in degenerative joint disease. Anabolic effects studied include ability to stimulate the synthesis of protein, collagen, proteoglycans, and Hyaluronic acid in various cells and tissues in vitro. Cultured human and rabbit chondrocytes have shown increased synthesis of proteoglycan and Hyaluronic acid in the presence of PSGAG. PSGAGs have shown a specific potentiating effect on Hyaluronic acid synthesis by synovial membrane cells in vitro.
Absorption, distribution, metabolism, and excretion of PSGAG following intramuscular injection have been studied in several species, including rats, rabbits, humans, horses and dogs.
Studies in rabbits showed maximum blood concentrations of PSGAG following IM injection were reached between 20 to 40 minutes following injection, and that the drug was distributed to all tissues studied, including Articular cartilage, synovial fluid, adrenals, thyroid, peritoneal fluid, lungs, eyes, spinal cord, kidneys, brain, liver, spleen, bone marrow, skin, and heart.
Following intramuscular injection of PSGAG in humans, the drug was found to be bound to serum proteins. PSGAG binds to both albumin and chi- and beta-globulins and the extent of the binding is suggested to be 30 to 40%. Therefore, the drug may be present in both bound and free form in the bloodstream. Because of its relatively low molecular weight, the synovial membrane is not a significant barrier to distribution of PSGAG from the bloodstream to the synovial fluid. Distribution from the synovial fluid to the cartilage takes place by diffusion. In the Articular cartilage the drug is deposited into the cartilage matrix.
Serum and synovial fluid distribution curves of PSGAG have been studied in dogs and appear similar to those found in humans and rabbits.
In rabbits, metabolism of PSGAG is reported to take place in the liver, spleen, and bone marrow. Metabolism may also occur in the kidneys. PSGAG administered intramuscularly and not protein bound or bound to other tissues is excreted primarily via the kidneys, with a small proportion excreted in the feces.
Dosage and Administration
The recommended dose of Adequan Canine is 2 mg/lb body weight (.02 mL/lb, or 1 mL per 50 lb), by intramuscular injection only, twice weekly for up to 4 weeks (maximum of 8 injections). Do not exceed the recommended dose or therapeutic regimen. Do not mix Adequan Canine with other drugs or solvents.
Contraindications
Do not use in dogs showing hypersensitivity to PSGAG. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders.
Precautions
Store at room temperature 18°-25°C (64°-77°F).
Use with caution in dogs with renal or hepatic impairment.
Caution
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Warning
Keep this and all medications out of reach of children.
Side Effects
In the clinical efficacy trial, 24 dogs were treated with Adequan Canine twice weekly for 4 weeks. Possible adverse reactions were reported after 2.1% of the injections. These included transient pain at the injection site (1 incident), transient diarrhea (1 incident each in 2 dogs), and abnormal bleeding (1 incident). These effects were mild and self-limiting and did not require interruption of therapy. To report suspected adverse reactions or for a copy of the Material Safety Data Sheet for this product, contact Luitpold Pharmaceuticals, Inc. at 1-800-458-0163.
Toxicology
In a subacute toxicity study, 32 adult beagle dogs (4 males and 4 females per treatment group) received either 0.9% saline solution or PSGAG at a dose of 5 mg, 15 mg, or 50 mg per kg of body weight (approximately 2.3, 6.8, or 22.7 mg/lb), via intramuscular injection twice weekly for 13 weeks. PSGAG doses represent approximately 1X, 3X, and 10X the recommended dosage of 2 mg/lb, and more than 3 times the recommended 4-week duration of treatment. Necropsies were performed 24 hours after the final treatment. During week 12, one dog in the 50 mg/kg dosage group developed a large hematoma at the injection site which necessitated euthanasia. No other mortalities occurred during the treatment period. Statistically significant changes in the 50 mg/kg group included increased prothrombin time, reduced platelet count, an increase in ALT and cholesterol, and increased liver and kidney weights. Increased cholesterol and kidney weights were also noted in the 15 mg/kg group. Microscopic lesions were noted in the liver (Kupffer cells containing eosinophilic foamy cytoplasm), kidneys (swollen, foamy cells in the proximal convoluted tubules), and lymph nodes (macrophages with eosinophilic foamy cytoplasm) in the 15 mg/kg and 50 mg/kg groups. Intramuscular inflammation, hemorrhage, and degeneration were seen in all 3 PSGAG treated groups; the incidence and severity appeared dose related.
Trial Data
Efficacy of Adequan Canine was demonstrated in two studies. A laboratory study using radio labeled PSGAG established distribution of PSGAG into canine serum and synovial fluid following a single intramuscular injection of 2 mg/lb. A clinical field trial was conducted in dogs diagnosed with radio graphically-confirmed traumatic and/or degenerative joint disease of 1 or 2 joints. Joints evaluated included hips, stifles, shoulders, hocks and elbows. Fifty-one dogs were randomly assigned to receive either Adequan Canine at 2 mg/lb of body weight or 0.9% saline. Both treatments were administered by intramuscular injection twice weekly for 4 weeks (8 injections total). Investigators administering treatment and evaluating the dogs were unaware of the treatment assignment. A total of 71 limbs in 51 dogs were evaluated. Of these, 35 limbs in 24 dogs were in the Adequan Canine treated group. Each lame limb was scored for lameness at a walk, lameness at a trot, pain, range of motion, and functional disability. The scores for the individual parameters were combined to determine a total orthopedic score. At the end of the treatment period, dogs treated with Adequan Canine showed a statistically significant improvement in range of motion and total orthopedic score over placebo treated control dogs.
Studies to establish the safety of Adequan Canine in breeding, pregnant, or lactating dogs have not been conducted.
-------------------------------------------------------------------------
Ik heb ervaring met beide, Alflutop 2x gebruikt het heeft zeker gewerkt alleen kwam de pijn later wel terug, dit omdat ik altijd hard bleef trainen, ben nu bezig met een vermindering van 80% 1RM naar 60% 1RM, train nu voor het eerst enkele weken pijnloos. Adequan (canine) gebruikt voor een tendinose van de schouder, heeft daarvoor echter niet geholpen, na mij achteraf beter in te lezen kwam ik er ook achter dat adequan niets kan doen bij een tendinose. Voor meer info moet je maar eens googlen, internet staat vol succes verhalen. Indien ontstekingsremmers, fysio etc zoals bij mij niet helpen, kan je dit zeker eens overwegen. Prijzen voor alfutop variëren van 20 tot 35€ per doosje(+evt verzending). Adequan (canine) 2x5ml kwam op 100$(+verzending en btw + evt invoerkosten, totaal via fedex was dit 180$, 3dagen later afgeleverd). (Ik ga ervanuit dat ik deze prijzen mag vermelden, aangezien dit geen aas is)
Laatst bewerkt:
